Eupraxia Pharmaceuticals (EPRX) Free Cash Flow (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Free Cash Flow of $326953.0 for Q1 2026, up 93.41% year-over-year from $169044.0 in Q1 2025, and up 133.21% quarter-over-quarter from -$984593.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Free Cash Flow (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Free Cash Flow for 4 consecutive years, with $326953.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 93.41% year-over-year to $326953.0; the TTM figure through Mar 2026 stood at -$431038.0 (down 842.81% YoY), while the FY2025 annual figure was -$29.1 million, up 3.18% from the prior year.
- Free Cash Flow climbed to $326953.0 in Q1 2026 per EPRX's latest filing, from -$984593.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $326953.0 in Q1 2026 and bottomed at -$984593.0 in Q4 2025.
- Historically, Free Cash Flow has averaged -$33815.2 across 4 years, with a median of $9602.0 in 2023.
- On a YoY basis, Free Cash Flow climbed as much as 2389.97% in 2025 and fell as far as 499.85% in 2025.
- Eupraxia Pharmaceuticals' Free Cash Flow stood at -$97369.0 in 2023, then slumped by 68.57% to -$164139.0 in 2024, then slumped by 499.85% to -$984593.0 in 2025, then soared by 133.21% to $326953.0 in 2026.
- Business Quant data shows EPRX's Free Cash Flow at $326953.0 in Q1 2026, -$984593.0 in Q4 2025, and $60377.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 326,953.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 326,953.00 |
| Mar 31, 2026 | 326,953.00 |
| Dec 31, 2025 | -984,593.00 |
| Dec 31, 2025 | -984,593.00 |
| Sep 30, 2025 | 60,377.00 |
| Sep 30, 2025 | 60,377.00 |
| Jun 30, 2025 | 166,225.00 |
| Jun 30, 2025 | 166,225.00 |
| Mar 31, 2025 | 169,044.00 |
| Mar 31, 2025 | 169,044.00 |
| Dec 31, 2024 | -164,139.00 |
| Dec 31, 2024 | -164,139.00 |
| Sep 30, 2024 | 42,275.00 |
| Sep 30, 2024 | 42,275.00 |
| Jun 30, 2024 | 10,848.00 |
| Jun 30, 2024 | 10,848.00 |
| Mar 31, 2024 | 6,789.00 |
| Mar 31, 2024 | 6,789.00 |
| Dec 31, 2023 | -97,369.00 |
| Dec 31, 2023 | -97,369.00 |